ICMR licenses three indigenous technologies for cancer, infections
ICMR licensed three indigenous biomedical technologies to Indian firms Emcure and Biological E for development, manufacturing and commercialization, including SHetA2 for CIN and two next-generation vaccines against enteric infections. The transfers, under initiatives like Medical Innovations Patent Mitra, aim to translate publicly funded research into affordable healthcare solutions and strengthen India's biomedical innovation ecosystem.
